

January 19, 2026

## KIMS Healthcare Management Limited: Ratings upgraded to [ICRA]AA-/[ICRA]A1+ and continue on Rating Watch with Developing Implications

### Summary of rating action

Instrument*	Previous Rated Amount (Rs. crore)	Current Rated Amount (Rs. crore)	Rating Action
Long-term – Fund-based/ Cash credit	25.00	19.00	[ICRA]AA-; upgraded from [ICRA]A+ and continues on Rating Watch with Developing Implications
Long-term – Fund-based/ Term loan	110.00	75.00	[ICRA]AA-; upgraded from [ICRA]A+ and continues on Rating Watch with Developing Implications
Short-term – Non-fund Based – Others	0.00	12.00	[ICRA]A1+; upgraded from [ICRA]A1 and continues on Rating Watch with Developing Implications
Long-term/ Short-term – Non-fund Based	12.00	0.00	-
Long-term/ Short-term – Unallocated	63.00	104.00	[ICRA]AA-/ [ICRA]A1+; upgraded from [ICRA]A+/[ICRA]A1 and continues on Rating Watch with Developing Implications
<b>Total</b>	<b>210.00</b>	<b>210.00</b>	

\*Instrument details are provided in Annexure-I

### Rationale

For arriving at the ratings, ICRA has taken consolidated view of KIMS Healthcare Management Limited (KHML) and its wholly-owned subsidiary, KIMS Nagercoil Institute of Medical Sciences Private Limited (KNIMSPL), which commenced its operations in October 2024, and considered consolidated financials of KHML, given the operational and financial linkages between the entities, and common management.

The ratings upgrade considers KIMS Healthcare Management Limited's (KHML) improved credit profile, marked by a healthy growth in revenues and earnings leading to a better financial profile. The addition of new beds and significant improvement in average revenue per occupied bed day (ARPOB) across hospitals led to a revenue growth of around 17% in H1 FY2026 (annualised) and around 15% in FY2025. The company is expected to add 500-600 beds (at the consolidated level) over the next two to three years in existing hospitals. The ramp-up of new capacity and a steady occupancy improvement at the existing capacity are expected to result in a healthy double digit revenue growth for the company in the near-to-medium term. The company's operating margin improved to around 26.5% in FY2025 from 23.3% in FY2024, benefitting from enhanced ARPOBs and improved cost structure, which is expected to sustain going forward. It benefitted significantly from business synergies with its parent entity, Quality Care India Limited (QCIL), given the centralised procurement, price rationalisation for select treatments and process efficiencies. A robust growth in revenues and earnings is expected to aid the company maintain healthy debt metrics with total debt / OPBITDA of less than 1.0 times and DSCR of over 5.0 times going forward.

The ratings continue to be on Watch with Developing Implications, given the proposed merger of QCIL with Aster DM Healthcare Limited (Aster DM, rated [ICRA]A+/[ICRA]A1+; on Rating Watch with Positive Implications) in a share swap transaction. The merger is expected to be completed by the end of Q1 FY2027, subject to regulatory approvals. The merged entity is likely to have 38 hospitals and seven medical centres across nine states and 27 cities, which will also include four brands under its umbrella, namely Aster DM, CARE Hospitals, KIMSHEALTH and Evercare. ICRA will monitor the impact of the proposed merger on KHML's operations / financial profile.

The ratings consider the strong brand reputation of KHML's flagship hospital at Trivandrum, as evident from the improved occupancy rate and ARPOB in the last two years. Further, the ratings continue to consider the long operational track record of

KHML in the healthcare segment and its diversified presence across different specialities as the top two specialities accounted for 20-25% of total revenues in the last two years. KHML's significant presence across multiple specialities helps it minimise the concentration risk. The ratings are, however, constrained by its high reliance on its Trivandrum facility, which contributed around 75% to the operating income (OI) and almost 85% to OPBITDA in FY2025, exposing KHML to geographical concentration risk. One of KHML's subsidiaries (KIMS Kottayam) has been reporting OPBITDA losses since it was acquired in 2013 because of its low occupancy and low-yielding speciality mix. Its other subsidiaries are also relatively smaller compared to the Trivandrum hospital, and hence account for a smaller share of earnings. The ratings also consider intense competition in Kerala, where retention of doctors would remain a key challenge. Moreover, the company's operations remain exposed to regulatory risks wherein any restrictive pricing guidelines would impact the company's margins.

## Key rating drivers and their description

### Credit strengths

**Strong brand reputation in Trivandrum** – KHML's flagship hospital at Trivandrum has a strong brand reputation in Kerala and the nearby districts of south Tamil Nadu. Further, the company benefits from the long operational track record and more than two decades of experience of the promoters in the healthcare industry.

**Diversified speciality mix** – The company has a diverse speciality mix with the top two specialities, oncology (9-11%) and general medicine (9-11%), accounting for 20-22% of its total revenues in FY2025. KHML's sizeable presence across multiple specialities helps minimise the concentration risk.

**Healthy financial profile** – The company's financial profile is comfortable, characterised by a healthy double digit revenue growth over the past few years, healthy profitability and comfortable debt metrics. Its revenue grew by around 15% in FY2025 and around 17% (annualised) in H1 FY2026, on the back of increase in ARPOB across all its hospitals, and commencement and successful ramp-up of new hospital in Nagercoil. The company is expected to continue registering a healthy revenue growth, going forward, on the back of significant occupancy and ARPOB. Its operating margin improved by 320 bps in FY2025 from 23.3% in FY2024, and is expected to improve further in FY2026, aided by higher scale and cost efficiencies stemming from operational synergies with QCIL. The company's capital structure remained comfortable with a gearing of 0.1 times as on March 31, 2025. Moreover, its debt coverage metrics also remained strong, as reflected in an interest coverage of 18.9 times (14.4 times in FY2024), DSCR to 6.1 times (from 3.8 times in FY2024), and TD/OPBITDA at 0.5 times in FY2025, supported by enhanced profitability. Despite the planned capex over the near-to-medium term, its debt coverage metrics are expected to remain comfortable.

### Credit challenges

**High dependence on Trivandrum hospital** – KHML is highly reliant on its Trivandrum facility, which contributed around 75.0% to its OI and around 85% to its OPBITDA in FY2025, leading to geographical concentration risk. Despite the bed addition plans across existing hospitals over the next 3-5 years, reliance on Trivandrum hospital is expected to continue. The company started a new hospital in Nagercoil in October 2024 with a capacity of around 210 beds (as of December 2025) at a project cost of Rs. 150.0 crore, funded through term debt of Rs. 90.0 crore and rest through equity from KHML. The company's ability to consequently improve OPBITDA levels at hospitals other than Trivandrum remains crucial to reduce its concentration risk.

**Regulatory risk and competition inherent to operations** – KHML is exposed to regulatory risks as any restrictive pricing on treatments and pharma sales would impact its margins. The company has high geographical concentration in Kerala and faces intense competition in the region from several large, reputed hospitals.

**Retention of doctors remain a key challenge** – The retention of doctors would remain a key challenge despite the competitive incentive mechanism currently offered by the entity.

## Liquidity position: Strong

KHML's liquidity position is strong, supported by healthy cash balances of Rs. 210-220.0 crore as on March 31, 2025, and unutilised working capital lines of around Rs. 33.4 crore as on September 30, 2025, as well as expected cash flow from operations of Rs. 350-400.0 crore over the next 12 months. In comparison, KHML's cumulative funding requirements for capital expenditure and repayment obligations are projected at Rs. 120-130.0 crore over the next 12 months, providing comfort to its liquidity profile.

## Rating sensitivities

**Positive factors** – The rating watch could be resolved as better clarity emerges on the proposed merger of its parent, QCIL, with Aster DM Healthcare Limited, along with more details on the support philosophy towards KHML. ICRA could upgrade KHML's ratings if there is a significant scale-up of operations while sustaining healthy operating margins, liquidity, and debt metrics.

**Negative factors** – Pressure on the ratings could arise if a large debt-funded capex or a material decline in operational performance results in a steep moderation in profitability or debt metrics on a sustained basis or adversely impact its liquidity profile. Specific credit metrics for ratings downgrade include TD/OPBIDTA above 1.5x times on a sustained basis.

## Analytical approach

Analytical Approach	Comments
Applicable rating methodologies	<a href="#">Corporate Credit Rating Methodology Hospitals</a>
Parent/Group support	As on September 30, 2025, QCIL held a 23.7% in KHML and a 90.3% in CIHPL, which, in turn, held a 61.5% in KHML. ICRA notes that QCIL is proposed to be merged with Aster DM, subject to regulatory and statutory approvals.
Consolidation/Standalone	For arriving at the ratings, ICRA has taken consolidated view of KIMS Healthcare Management Limited and KIMS Nagercoil Institute of Medical Sciences Private Limited and considered the consolidated financials of KHML. As on March 31, 2025, the company had six subsidiaries, which are enlisted in Annexure-II

## About the company

KHML was set up in 2002 by a group of professionals in Trivandrum. It is a tertiary and quaternary-care hospital, with 40 speciality departments. The hospital has been accredited by the National Accreditation Board for Hospitals (NABH), the Australian Council on Healthcare Standard International (ACHSI), the National Accreditation Board for Laboratories (NABL), and the NABH Accredited Blood Bank. As on December 31, 2025, the company had five operational hospitals, spread across Trivandrum, Kottayam, Kollam, Perinthalmanna in Kerala and Nagercoil in Tamil Nadu, with a total capacity of 1,560. The company also operates seven medical centres in Trivandrum. The company has investments from a private equity investor, Blackstone Inc., through Condis India Healthcare Private Limited (CIHPL) and QCIL. As on September 30, 2025, CIHPL (QCIL held a 90.3% stake in CIHPL) held a 61.5% stake in KHML, and QCIL held a 23.7% stake in KHML, while the remaining 14.8% stake was held by individual shareholders.

**Key financial indicators (audited)**

<b>KHML Consolidated</b>	<b>FY2024</b>	<b>FY2025</b>
<b>Operating income</b>	1,103.0	1,264.8
<b>PAT</b>	152.7	217.3
<b>OPBDIT/OI</b>	23.3%	26.5%
<b>PAT/OI</b>	13.8%	17.2%
<b>Total outside liabilities/Tangible net worth (times)</b>	0.3	0.3
<b>Total debt/OPBDIT (times)</b>	0.5	0.5
<b>Interest coverage (times)</b>	14.4	18.9

Source: Company, ICRA Research; All ratios as per ICRA's calculations; Amount in Rs. crore; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

**Status of non-cooperation with previous CRA: Not applicable**

**Any other information: None**

### Rating history for past three years

Instrument	Current rating (FY2026)			Chronology of rating history for the past 3 years					
	Type	Amount rated (Rs. crore)	Jan 19, 2026	FY2025		FY2024		FY2023	
				Date	Rating	Date	Rating	Date	Rating
Term loans	Long term	75.00	[ICRA]AA-; Rating Watch with Developing Implications	Dec 24, 2024	[ICRA]A+; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable)	Jul 28, 2022	[ICRA]A (Stable)
						Nov 06, 2023	[ICRA]A; Rating watch with Developing Implications		
Cash credit	Long term	19.00	[ICRA]AA-; Rating Watch with Developing Implications	Dec 24, 2024	[ICRA]A+; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable)	Jul 28, 2022	[ICRA]A (Stable)
						Nov 06, 2023	[ICRA]A; Rating watch with Developing Implications		
BG/LC	Long term / Short term	0.00	-	Dec 24, 2024	[ICRA]A+ / [ICRA]A1; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable) / [ICRA]A2+	Jul 28, 2022	[ICRA]A (Stable) / [ICRA]A2+
						Nov 06, 2023	[ICRA]A / [ICRA]A2+; Rating watch with Developing Implications		
Non-fund Based – Others	Short-term	12.00	[ICRA]A1+; Rating Watch with Developing Implications	-	-	-	-	-	-
Unallocated	Long term / Short term	104.00	[ICRA]AA- / [ICRA]A1+; Rating Watch with Developing Implications	Dec 24, 2024	[ICRA]A+ / [ICRA]A1; Rating Watch with Developing Implications	Aug 14, 2023	[ICRA]A (Stable) / [ICRA]A2+	Jul 28, 2022	[ICRA]A (Stable) / [ICRA]A2+
						Nov 06, 2023	[ICRA]A / [ICRA]A2+; Rating watch with Developing Implications		

## Complexity level of the rated instruments

Instrument	Complexity Indicator
Long-term – Fund-based/ Cash credit	Simple
Long-term – Fund-based/ Term loan	Simple
Long-term/ Short-term – Non-fund based	Simple
Short-term – Non-fund based – Others	Simple
Long-term/ Short-term – Unallocated	Not applicable

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

**Annexure I: Instrument details**

ISIN	Instrument Name	Date of Issuance	Coupon Rate	Maturity	Amount Rated (Rs. crore)	Current Rating and Outlook
NA	Term loan	FY2020	NA	FY2030	75.00	[ICRA]AA-; Rating Watch with Developing Implications
NA	Cash credit	NA	NA	NA	19.0	[ICRA]AA-; Rating Watch with Developing Implications
NA	Bank guarantee	NA	NA	NA	6.0	[ICRA]A1+; Rating Watch with Developing Implications
NA	Letter of credit	NA	NA	NA	6.0	[ICRA]A1+; Rating Watch with Developing Implications
NA	Unallocated limits	NA	NA	NA	104.00	[ICRA]AA-/ [ICRA]A1+; Rating Watch with Developing Implications

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

**Annexure II: List of entities considered for consolidated analysis**

Company Name	KHML Ownership	Consolidation Approach
KIMS Healthcare Management Limited	100.0% (rated entity)	Full Consolidation
KIMS Al Shifa Healthcare Private Limited	51.0%	Full Consolidation
KIMS Kottayam Institute of Medical Sciences Private Limited	100.0%	Full Consolidation
KIMS Kollam Multi Specialty Hospital India Private Limited	100.0%	Full Consolidation
KIMS Nagercoil Institute of Medical Sciences Private Limited	100.0%	Full Consolidation
Spiceretreat Hospitality Services Private Limited	100.0%	Full Consolidation
KIMS HEALTH Executive Leisure Private Limited	100.0%	Full Consolidation

Source: KHML; Stake as on September 30, 2025

Note: ICRA has considered consolidated financials of the KHML and its subsidiaries while assigning the ratings.

## ANALYST CONTACTS

**Jitin Makkar**

0124 4545 368

[jitinm@icraindia.com](mailto:jitinm@icraindia.com)

**Nithya Debbadi**

+91 40 6939 6416

[nithya.debbadi@icraindia.com](mailto:nithya.debbadi@icraindia.com)

**Srikumar K**

+91 44 4596 4318

[ksrikumar@icraindia.com](mailto:ksrikumar@icraindia.com)

**Raviteja Etikala**

+91 40 6939 6418

[etikala.teja@icraindia.com](mailto:etikala.teja@icraindia.com)

## RELATIONSHIP CONTACT

**L. Shivakumar**

+91 22 6114 3406

[shivakumar@icraindia.com](mailto:shivakumar@icraindia.com)

## MEDIA AND PUBLIC RELATIONS CONTACT

**Ms. Naznin Prodhani**

Tel: +91 124 4545 860

[communications@icraindia.com](mailto:communications@icraindia.com)

## HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

[info@icraindia.com](mailto:info@icraindia.com)

## ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit [www.icra.in](http://www.icra.in)

## ICRA Limited




### Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



### Branches



© Copyright, 2026 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website [www.icra.in](http://www.icra.in) or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents